Bukwang Pharmaceutical will launch Ariplus Tablets 10/20mg (donepezil hydrochloride hydrate and memantine hydrochloride) on March 1, a combination drug for the treatment of Alzheimer's disease.

Unlike existing treatments, Ariplus combines two ingredients in a single tablet to make it more convenient for patients with moderate to severe Alzheimer's disease. Its combination form improves medication adherence and reduces the burden on patients and their caregivers.

Ariplus was jointly developed by eight companies, including Bukwang, which received the product license from the Ministry of Food and Drug Safety last December.

“Ariplus Tablet is the first combination product to combine donepezil and memantine, which is expected to reduce the number of medications taken by patients, improving convenience and treatment effectiveness,” a Bukwang Pharmaceutical official said. “We will continue to conduct research and support to provide meaningful treatment options for Alzheimer's disease patients and their caregivers.”

The official continued, “As we look forward to the launch of Ariplus Tablets, we will continue to focus on expanding into other diseases related to the central nervous system (CNS), such as schizophrenia and bipolar disorder, where we have recently focused our efforts.”